S&P 500   5,251.31 (+0.05%)
DOW   39,763.21 (+0.01%)
QQQ   444.35 (-0.11%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.26 (+0.31%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.26 (+1.53%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.65 (-2.48%)
DIS   122.77 (+1.48%)
AMC   3.70 (-14.75%)
PFE   27.89 (+0.40%)
PYPL   67.61 (+1.56%)
XOM   115.72 (+0.65%)
S&P 500   5,251.31 (+0.05%)
DOW   39,763.21 (+0.01%)
QQQ   444.35 (-0.11%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.26 (+0.31%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.26 (+1.53%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.65 (-2.48%)
DIS   122.77 (+1.48%)
AMC   3.70 (-14.75%)
PFE   27.89 (+0.40%)
PYPL   67.61 (+1.56%)
XOM   115.72 (+0.65%)
S&P 500   5,251.31 (+0.05%)
DOW   39,763.21 (+0.01%)
QQQ   444.35 (-0.11%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.26 (+0.31%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.26 (+1.53%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.65 (-2.48%)
DIS   122.77 (+1.48%)
AMC   3.70 (-14.75%)
PFE   27.89 (+0.40%)
PYPL   67.61 (+1.56%)
XOM   115.72 (+0.65%)
S&P 500   5,251.31 (+0.05%)
DOW   39,763.21 (+0.01%)
QQQ   444.35 (-0.11%)
AAPL   171.14 (-1.25%)
MSFT   420.29 (-0.27%)
META   486.02 (-1.59%)
GOOGL   150.58 (-0.19%)
AMZN   179.90 (+0.04%)
TSLA   177.35 (-1.38%)
NVDA   905.26 (+0.31%)
NIO   4.61 (-1.28%)
AMD   181.80 (+1.23%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.26 (+1.53%)
MU   118.03 (-0.93%)
CGC   9.83 (+2.93%)
GE   175.65 (-2.48%)
DIS   122.77 (+1.48%)
AMC   3.70 (-14.75%)
PFE   27.89 (+0.40%)
PYPL   67.61 (+1.56%)
XOM   115.72 (+0.65%)
NASDAQ:SVRA

Savara (SVRA) Stock Price, News & Analysis

$4.92
+0.07 (+1.44%)
(As of 12:27 PM ET)
Today's Range
$4.84
$4.93
50-Day Range
$4.27
$5.59
52-Week Range
$1.63
$5.70
Volume
283,426 shs
Average Volume
814,039 shs
Market Capitalization
$679.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.20

Savara MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
69.1% Upside
$8.20 Price Target
Short Interest
Bearish
5.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Savara in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$884,741 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.38) to ($0.30) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.96 out of 5 stars

Medical Sector

565th out of 939 stocks

Pharmaceutical Preparations Industry

266th out of 435 stocks

SVRA stock logo

About Savara Stock (NASDAQ:SVRA)

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

SVRA Stock Price History

SVRA Stock News Headlines

Savara Announces New Employment Inducement Grant
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
SVRA Jul 2024 7.500 call
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Best penny stocks of March 2024
Piper Sandler Keeps Their Buy Rating on Savara (SVRA)
Savara Inc. (YB4P.F)
Savara Inc. (NASDAQ:SVRA): Are Analysts Optimistic?
Savara added to Nasdaq Biotechnology Index
Savara Added to the NASDAQ Biotechnology Index
Savara Inc SVRA
See More Headlines
Receive SVRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/28/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SVRA
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.20
High Stock Price Target
$16.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+69.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-54,700,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.04 per share

Miscellaneous

Free Float
131,821,000
Market Cap
$670.03 million
Optionable
Optionable
Beta
0.77
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Robert N. Neville (Age 51)
    Chairman of the Board, Chief Executive Officer
  • Taneli Jouhikainen (Age 51)
    President, Chief Operating Officer
  • David L. Lowrance (Age 50)
    Chief Financial Officer
  • Nevan C. Elam (Age 49)
    Independent Director
  • Richard J. Hawkins (Age 68)
    Independent Director
  • Joseph S. McCracken Ph.D. (Age 64)
    Independent Director
  • Matthew Pauls J.D.Matthew Pauls J.D. (Age 46)
    Independent Director
  • Yuri Pikover (Age 56)
    Independent Director

SVRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Savara stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SVRA shares.
View SVRA analyst ratings
or view top-rated stocks.

What is Savara's stock price target for 2024?

5 Wall Street analysts have issued twelve-month price objectives for Savara's shares. Their SVRA share price targets range from $4.00 to $16.00. On average, they expect the company's stock price to reach $8.20 in the next year. This suggests a possible upside of 69.1% from the stock's current price.
View analysts price targets for SVRA
or view top-rated stocks among Wall Street analysts.

How have SVRA shares performed in 2024?

Savara's stock was trading at $4.70 at the beginning of 2024. Since then, SVRA stock has increased by 3.2% and is now trading at $4.85.
View the best growth stocks for 2024 here
.

When is Savara's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our SVRA earnings forecast
.

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) issued its quarterly earnings data on Thursday, March, 7th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.02.

What other stocks do shareholders of Savara own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP).

Who are Savara's major shareholders?

Savara's stock is owned by a number of retail and institutional investors. Top institutional investors include Jennison Associates LLC (6.51%), Vanguard Group Inc. (4.37%), Vanguard Group Inc. (4.28%), Vivo Capital LLC (1.54%), Wellington Management Group LLP (1.52%) and Nantahala Capital Management LLC (0.73%). Insiders that own company stock include Badrul A Chowdhury, David A Ramsay, David L Lowrance, Matthew Pauls, Nevan C Elam, Raymond Dennis Pratt and Rick Yang.
View institutional ownership trends
.

How do I buy shares of Savara?

Shares of SVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SVRA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners